The research focus of the Nolin laboratory includes characterizing the impact of kidney disease and renal replacement therapy on drug exposure (clinical pharmacokinetics) and response (pharmacodynamics), evaluating the functional expression of drug metabolizing enzymes and transporters, developing novel quantitative analytical techniques, and assessing the implications of using various kidney function estimating equations on drug eligibility, selection, and dosing. The long-range goal of our research is to identify the mechanisms by which kidney disease contributes to alterations in these drug elimination pathways, to understand the impact of these alterations on drug response and patient outcomes, and ultimately, to use this information in the development of strategies to optimize drug use in patients with kidney disease.
Dr. Nolin has a strong record of interdisciplinary and interinstitutional collaborations with regulatory, pharmaceutical industry, and academic scientists in the conduct of clinical-translational studies. He served as chair of the Kidney Health Initiative workgroup to assess pharmacokinetics during RRT and as co-chair of the Extracorporeal Treatments in Poisoning (EXTRIP) Workgroup.
Dr. Nolin's clinical interest revolves around medication use in people with kidney disease. Ultimately, by improving our understanding of the impact of kidney disease and renal replacement therapy (RRT) on drug exposure (pharmacokinetics) and response (pharmacodynamics) we will be better able to identify the right medications and doses for our patients.
- BS, Pharmacy, University of Connecticut, 1989
- MS, Pharmacy, University of North Carolina, 1991
- PharmD, University of Pittsburgh, 1999
- PhD, University of Pittsburgh, 2003
- Residency, Pharmacy, UNC Hospitals, 1991
